Arrowhead Pharmaceuticals, Inc. ARWR

What this company does

Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Its first commercial product, REDEMPLO (plozasiran), is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome. Eighteen Arrowhead-discovered drug candidates are in clinical trials, ranging from early stage to late stage. As of September 30, 2025, it employed 711 full-time employees based at four facilities in the United States. Its TRiM platform uses ligand-mediated delivery and is designed to enable tissue-specific targeting. It has entered into license and collaboration agreements with companies including Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited and Novartis Pharma AG, for programs it does not commercialize independently. The company operates research laboratory facilities in San Diego, California, and Madison, Wisconsin, where its pre-clinical research and development takes place. It manufactures drug substance under current Good Manufacturing Practices at a manufacturing and laboratory facility in Verona, Wisconsin.

Written from the business description in ARROWHEAD PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 25 November 2025. Every sentence was checked against that document before publication.